The impact of perioperative synbiotic treatment on improvement of morbidity and survival after major hepato-biliary-pancreatic surgery.

The impact of perioperative synbiotic treatment on improvement of morbidity and survival after major hepato-biliary-pancreatic surgery. - SYMBIO-HBP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000048241

Enrollment

100

Registered

2022-07-11

Start date

2022-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer, biliary tract cancer, pancreatic cancer

Interventions

Symbiotic treatment (Clostridium butyricum miyairi 588 and GFO (Glutamine, Fiber, and Oligosaccharide)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with hepato-biliary-pancreatic cancers who will undergo the operation.

Exclusion criteria

Exclusion criteria: Patients who do not consent to attend the study. Patients who have already taken the Probiotics when they receive the informed consent.

Design outcomes

Primary

Measure	Time frame
incidence of postoperative complication, completion rate of adjuvant therapy	—

Secondary

Measure	Time frame
Assessment of sarcopenia PNI (prognostic nutritional index) Assessment of bacterial flora in the discharge of abdominal drain and stool Serum cytokine Recurrence free survival Overall survival	—

Countries

Japan

Contacts

Public ContactIkuo Nakamura

Hyogo Medical University Department of Gastroenterological Surgery

ikuon@hyo-med.ac.jp0798-45-6582

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026